A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer

Annals of Oncology

Volumn 9, Issue 11, 1998, Pages 1179-1184

  Makris, A ^a,b   Powles, T J ^a   Ashley, S E ^a   Chang, J ^a   Hickish, T ^a   Tidy, V A ^a   Nash, A G ^a   Ford, H T ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Chemotherapy; Mastectomy; Neoadjuvant; Tamoxifen

Indexed keywords

METHOTREXATE; MITOMYCIN C; MITOXANTRONE; TAMOXIFEN;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MASTECTOMY; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0031743702     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008400706949     Document Type: Article

References (19)

1. Hortobagyi GN, Ames FC, Buzdar AU et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 1988: 62: 2507-16.
2. Jacquillat C, Weil M, Baillet F et al. Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 1990; 66: 119-29.
3. Fisher B, Saffer EA, Rudock C et al. Presence of a growth stimulating factor in serum following primary tumor removal in mice. Cancer Res 1989; 49: 1996-2001.
4. Fisher B, Saffer EA, Ruddock C et al. Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth stimulating factor in mice. Cancer Res 1989; 49: 2002-4.
5. Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727-33.
6. Powles TJ, Hickish TF, Makris A et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 1995: 13: 547-52.
7. Hayward JL, Carbone PP, Heuson JC et al. Assessment of response to therapy in advanced breast cancer. Br J Cancer 1977: 35: 292-8.
8. Montes A, Powles TJ, O'Brien MER et al. A toxic interaction between mitomycin-C and tamoxifen causing the haemolytic uraemic syndrome. Eur J Cancer 1993; 29A: 1854-7.
9. Mansi JL, Smith IE, Walsh G et al. Primary medical treatment for operable breast cancer. Eur J Clin Oncol 1989; 25: 1623-7.
10. Smith IE, Jones AL, O'Brien MER et al. Primary medical (neoadjuvant) chemotherapy for operable breast cancer. Eur J Cancer 1993: 29A (12): 1796-9.
11. Bonadonna G, Veronesi U, Brambilla C et al. Primary chemotherapy to avoid mastectomy in tumors with diameter of three centimeters or more. J Natl Cancer Inst 1990: 82: 1539-45.
12. Scholl SM, Fourquet A, Asselain B et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6. Eur J Cancer 1994: 30A (5): 645-52.
13. Mauriac L, Durand M, Avril A et al. Effects of primary chemotherapy in conservative treatmenl of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol 1991; 2: 347-54.
14. Fisher B, Brown A, Mamounas E et al. Effect of preoperative therapy for primary breast cancer (BC) on local-regional disease, disease-free survival (DFS) and survival (S): Results from NSABP B-18. Proc Annu Meet Am Soc Clin Oncol 1997; 16: 127 (Abstr 449).
15. Scholl SM, Pierga JY, Asselain B et al. Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 1996; 31A (12): 1969-75.
16. Early Breast Cancer Triallists' Collaborative Group. Systemic treatmenl of early breast cancer by hormonal, cytotoxic. or immune therapy. One hundred Ihirty-three randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339: 1-15.
17. Pierquin B, Owen R, Maylin C et al. Radical radiation therapy of breast cancer, Int J Radiat Oncol Biol Phys 1980; 6: 17-24.
18. Amalric R, Santamaria F, Robert F et al. Radiation therapy with or without primary limited surgery for operable breast cancer: A 20-year experience at the Marsaille Cancer Institute. Cancer 1982: 49: 30-4.
19. Van Limbergen E, Van der Schueren E, Van den Bogaert W et al. Local control of operable breast cancer after radiotherapy alone. Eur J Cancer 1990; 26: 674-9.